Objectives

After participating in this educational activity, attendees should be able to:

1|Summarize the pathophysiology of heart failure with reduced ejection fraction (HFrEF) & iron-deficiency in HFrEF
2|Interpret iron studies for diagnosis of iron-deficiency
3|Demonstrate understanding of previous trials utilizing iron therapy in patients with HFrEF
4|Examine and evaluate the methods, outcomes, and results of the FAIR-HF2 DZHKO5 RCT
5|Apply trial findings to associated current practice settings
6|Describe the mechanism of action of blinatumomab and its use in current chemotherapy regimens
7|Recognize the timeline of treatment for pediatric B-ALL
8|Analyze recent literature pertaining to the use of blinatumomab in pediatric B-ALL
9|Define blinatumomab’s place in therapy for pediatric B-ALL

 

Presenter(s): 
Ashley McNamara, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
 
Sabrina Pham, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Ashley McNamara, PharmDSpeaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Sabrina Pham, PharmDSpeaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Session date: 
10/20/2025 - 2:00pm to 3:00pm EDT
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 ACPE Technician contact hours
Please login or register to take this course.